Related Experiment Video
Updated: Jul 5, 2026
09:02
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
AIT-082 NeoTherapeutics Inc
1Director of Cell Physiology, Life Sciences, Janssen Research Foundation, Turnhoutseweg 30, B-2340 Beerse, Belgium. hgeerts@janbelc1.ssw.jnj.com
Idrugs : the Investigational Drugs Journal
|May 10, 2008
Summary
AIT-082, an orally-active nerve growth factor (NGF) agonist, demonstrated memory improvement in Alzheimer's patients and enhanced memory function in mice. Preclinical studies showed AIT-082 increased neurotrophic factors, suggesting potential for neurological disorders.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Development
Background:
- Alzheimer's disease (AD), stroke, and motor neuron disease are debilitating neurological conditions.
- Nerve growth factor (NGF) agonists are being investigated as potential therapeutic agents.
- AIT-082 is an orally-active NGF agonist developed by NeoTherapeutics.
Purpose of the Study:
- To evaluate the safety and efficacy of AIT-082 in Alzheimer's disease patients.
- To assess the pharmacokinetic profile of AIT-082 in healthy elderly volunteers.
- To investigate the effects of AIT-082 on memory function and neurotrophic factors in preclinical models.
Main Methods:
- Phase II safety and efficacy trial in AD patients.
- Phase I multiple-dose pharmacokinetic study in healthy elderly volunteers.
- Preclinical studies in mice and rats involving memory tests and neurotrophic factor analysis.
Main Results:
- AIT-082 improved memory in 60% of AD patients in a phase I/II trial.
- Oral administration of AIT-082 was well-tolerated in healthy volunteers.
- AIT-082 enhanced memory in mice, prevented age-related deficits, and restored memory after brain lesions.
- AIT-082 increased neurotrophic factors (NT-3, CNTF, BDNF) in preclinical models.
Conclusions:
- AIT-082 shows promise as a treatment for Alzheimer's disease and other neurological disorders.
- The drug's ability to enhance memory and increase neurotrophic factors warrants further investigation.
- AIT-082's oral bioavailability and tolerability support its continued development.
